

February 14, 2025

BSE Limited
Phiroze Jeejeebhai Towers,
Dalal Street,
Mumbai – 400001
Scrip Code – 526783

Dear Sir/ Madam,

Subject: Integrated Filing (Financial) for the quarter and the nine months ended December 31, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 dated January 02, 2025, we enclose herewith the Integrated Filing (Financial) for the quarter and the nine months ended December 31, 2024. We request you to take the above on record.

Yours truly
For **Dr. Agarwal's Eye Hospital Limited**

Meenakshi Jayaraman
Company Secretary & Compliance Officer

INTEGRATED FILING (FINANCIALS)

A. UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024, (STANDALONE) – **Enclosed**

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. – **Not Applicable**

C. OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – **No default, hence Not Applicable**

D. DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half yearly filings i.e., 2nd and 4th quarter) – **Not Applicable**


E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (applicable only for Annual Filing i.e., 4th quarter) – **Not Applicable**

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter and nine months ended 31 December 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



R. Prasanna Venkatesh

R. Prasanna Venkatesh
(Partner)
(Membership No. 214045)

Place: Chennai
Date: 14 February 2025
UDIN: 25214045BMNWA9191

Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals

Eye Hospital


(Amount in INR Crores except EPS)

Statement of Unaudited Financial Results for the Quarter and Nine months ended 31st December 2024

S.No.	Particulars	Quarter Ended			Nine months ended		Year Ended
		31-Dec-24 Unaudited	30-Sep-24 Unaudited	31-Dec-23 Unaudited	31-Dec-24 Unaudited	31-Dec-23 Unaudited	31-Mar-24 Audited
1	Income						
	(a) Revenue from Operations	95.11	102.19	75.95	297.32	238.59	319.30
	(b) Other Income	2.31	2.28	0.67	4.99	2.50	4.97
	Total Income	97.42	104.47	76.62	302.31	241.09	324.27
2	Expenses						
	(a) Purchase of Stock-in-Trade	10.89	9.07	8.68	34.08	27.10	35.95
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	(0.68)	1.88	(0.62)	(2.77)	(1.69)	(2.25)
	(c) Surgical Lens including other consumables	11.86	12.95	9.55	36.70	27.84	36.85
	(d) Consultancy Charges for Doctors (net) (Refer Note 3)	11.66	13.53	11.94	39.43	36.65	48.37
	(e) Employee Benefit Expenses	20.90	19.90	15.51	58.37	48.37	63.78
	(f) Finance Costs	3.85	3.67	1.83	10.55	5.14	7.17
	(g) Depreciation and Amortisation Expense	10.02	9.36	6.89	29.25	19.08	26.61
	(h) Other Expenses	14.86	14.98	10.12	44.60	33.69	45.54
	Total Expenses	83.36	85.34	63.90	250.21	196.18	262.02
3	Profit before tax (1-2)	14.06	19.13	12.72	52.10	44.91	62.25
4	Tax Expense						
	- Current Tax	3.85	4.73	3.38	13.79	11.52	16.22
	- Deferred Tax (Net)	(0.19)	0.25	(0.10)	(0.35)	(0.18)	(0.33)
	Total Tax Expense	3.66	4.98	3.28	13.44	11.34	15.89
5	Profit after tax (3-4)	10.40	14.15	9.44	38.66	33.57	46.36
6	Other Comprehensive Income						
	(a) Items that will not be reclassified to the Statement of Profit and Loss						
	- Actuarial (loss) / gain on defined benefit obligation	(0.12)	(0.28)	(0.33)	(0.37)	(0.98)	0.05
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	0.03	0.07	0.09	0.09	0.26	(0.01)
	Total Other Comprehensive income / (loss) (net of tax)	(0.09)	(0.21)	(0.24)	(0.28)	(0.72)	0.04
7	Total Comprehensive Income (5+6)	10.31	13.94	9.20	38.38	32.85	46.40
8	Paid-up equity share capital (Face value INR 10/- each)	4.70	4.70	4.70	4.70	4.70	4.70
9	Reserves (Other Equity)						152.45
10	Earnings Per Equity Share (EPS) (Face value of INR 10/- each)						
	(a) Basic	22.13	30.11	20.09	82.26	71.43	98.64
	(b) Diluted	22.13	30.11	20.09	82.26	71.43	98.64
		(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)
	Additional Information:						
	Earnings before finance cost, depreciation, amortisation and tax (EBITDA) (Refer Foot Note 1)	27.93	32.16	21.44	91.90	69.13	96.03

Foot Note:

The company has presented information on EBITDA additionally as a part of the statement of unaudited financial results as defined above.



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

Notes to the Statement of Unaudited Financial Results for the Quarter and Nine months ended 31st December 2024

- 1 The unaudited financial results, which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. The statutory auditors of the Company have performed a limited review of the unaudited financial results for the quarter and nine months ended 31st December 2024 and have issued an unmodified review report on these results.
- 2 The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th February 2025.
- 3 The Board of Directors of Dr. Agarwals Health Care Limited, the company's holding company, at its meeting held on 20th December 2024, approved the withdrawal of the Doctor Incentive Plan. Accordingly, the Company has written back a total liability of INR 1.55 Crores which has been accounted in Consultancy Charges for Doctors for the quarter and nine months ended 31st December 2024.
- 4 The Company operates in a single segment i.e. "Eye Care related sales and services" and does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
- 5 Figures for the previous periods wherever necessary, have been regrouped / reclassified to conform to the current period's presentation



By order of the Board

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684

Place : Chennai

Date : 14th February 2025



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

(Amount in INR Crores except EPS)

Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2024

Particulars	Quarter Ended			Nine months ended		Year ended
	31-Dec-24 Unaudited	30-Sep-24 Unaudited	31-Dec-23 Unaudited	31-Dec-24 Unaudited	31-Dec-23 Unaudited	31-Mar-24 Audited
Revenue from Operations	95.11	102.19	75.95	297.32	238.59	319.30
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	14.06	19.13	12.72	52.10	44.91	62.25
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	14.06	19.13	12.72	52.10	44.91	62.25
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	10.40	14.15	9.44	38.66	33.57	46.36
Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	10.31	13.94	9.20	38.38	32.85	46.40
Paid-up Equity Share Capital (Face Value of INR 10/- each)	4.70	4.70	4.70	4.70	4.70	4.70
Reserves (Other Equity)						152.45
Earnings Per Share (for continuing and discontinued operations) (Face Value of INR 10/- each):						
(a) Basic	22.13	30.11	20.09	82.26	71.43	98.64
(b) Diluted	22.13	30.11	20.09	82.26	71.43	98.64
	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

Notes:

1) The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).

Place : Chennai
Date : 14th February 2025



By order of the Board

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684